Develops drugs for central nervous system diseases.
Jun 2026Revenue $830M/yrExpenses $961M/yr
No trend
Figures by year
When will Supernus Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $830M and expenses $961M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $719M | $781M | −$62.3M |
| Dec 2024 | $662M | $580M | $81.7M |
| Dec 2023 | $608M | $613M | −$5.27M |
| Dec 2022 | $667M | $621M | $46.1M |
| Dec 2021 | $580M | $494M | $86.0M |
| Dec 2020 | $520M | $347M | $174M |
| Dec 2019 | $393M | $244M | $149M |
| Dec 2018 | $409M | $264M | $144M |
| Dec 2017 | $302M | $203M | $99.5M |
| Dec 2016 | $215M | $161M | $54.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.